<PAGE>   1


                                                                  EXHIBIT 10.83f

                 SUBSTITUTE NON-STATUTORY STOCK OPTION AGREEMENT

         THIS SUBSTITUTE NON-STATUTORY STOCK OPTION AGREEMENT ("Agreement")
entered into as of the 26th day of September, 1996 by and between Pharmaceutical
Product Development, Inc., a North Carolina corporation (the "Company") and
Grover C. Wrenn (the "Executive").

                                   WITNESSETH:

         WHEREAS, the Company has agreed, pursuant to the Agreement and Plan of
Reorganization by and among the Company, Wilmington Merger Corp., a North
Carolina corporation and wholly-owned subsidiary of the Company, and Applied
Bioscience International Inc., a Delaware corporation ("APBI") (the "Merger
Agreement"), to assume certain of the non-statutory stock options (the
"Options") granted to the Executive in connection with the Separation Agreement
dated August 25, 1995, entered into by and between the Executive and APBI (the
"Separation Agreement"); and

         WHEREAS, pursuant to the terms of the Merger Agreement, the Executive
is entitled to receive substitute options denominated in shares of common stock
of the Company, in substitution for and cancellation of the Options, provided
that the substitute options shall be subject to the terms and conditions of this
agreement and the Pharmaceutical Product Development, Inc. Equity Compensation
Plan (the "Plan") except that the number of shares of the Company's common stock
and the exercise price of the option are to be adjusted in the manner set forth
in the Merger Agreement and the substitute options are to have substantially the
same restrictions, terms and conditions as the options for which they were
substituted.

         NOW, THEREFORE, intending to be legally bound hereby, the Company and
the Executive do hereby covenant and agree as follows:

         1. SUBSTITUTE OPTION. Pursuant to the terms of the Merger Agreement,
the Company does hereby issue to the Executive in substitution for the option
granted to the Executive on September 19, 1995, by APBI to replace the original
option granted to the Executive on September 13, 1994, the right and option to
purchase, under the terms and conditions hereinafter set forth, in whole or in
part, 20,270 shares of common stock of the Company, par value $.10 per share,
which right and option shall not constitute an incentive stock option within the
meaning of Section 422(b) of the Internal Revenue Code of 1986, (the
"Non-Statutory Stock Option"). The price at which the shares shall be purchased
shall be $14.50, which price is the adjusted exercise price of the Non-Statutory
Stock Option as determined under the Merger Agreement.

         2. TERMS. The Non-Statutory Stock Option herein granted shall expire at
12:00 midnight on the earlier of (a) February 11, 2001, or (b) the day
immediately following any period of twenty (20) consecutive trading days in
which the last sale for shares of the Company's

<PAGE>   2

Common Stock (as adjusted for stock splits, dividends, and similar events) for
each of such trading days equaled or exceeded $49.33 per share as quoted on the
NASDAQ National Market System. The Executive may at any time exercise this
option to acquire 13,513 shares. Thereafter, the Executive may exercise this
option in cumulative annual installments of portions of the shares covered by
the option, as follows:

                    Date                               Number of Shares

       on or after September 13, 1997                        6,757

         3. EXERCISE. The Executive may exercise the Non-Statutory Stock Option
granted hereunder by giving written notice to the Compensation Committee of the
Company ("the Committee") at 3151 S. 17th Street Extension, Wilmington,
North Carolina 28412. Such notice, a form of which is attached hereto as Exhibit
A and incorporated by reference, shall state the number of full shares (no
fractional shares may be purchased) to which the election applies. Such notice
shall be accompanied by payment in an amount sufficient to purchase the number
of shares set forth in the notice at the per share price established by Section
1 hereof. Payment shall be made in cash, or the Committee in its discretion may
allow the Executive to use shares of the Company's Common Stock having a fair
market value equal to the purchase price (as determined by the Committee), or
the Committee may allow the use of a combination of cash and such shares.

         4. DEATH. In the event of death of the Executive, the Non-Statutory
Stock Option shall be exercisable by the person or persons who acquired the
option by bequest or inheritance or by reason of the death of the Executive, or
by the executor or administrator of the estate of the deceased Executive at any
time before the expiration date of the Non-Statutory Stock Option.

         5. NO IMPLIED RIGHTS. Nothing contained in this Agreement, nor the
granting of any options hereunder, shall be construed as giving the Executive or
any other person any legal or equitable rights against the Company or any
subsidiary corporation or any director, officer, employee or agent thereof,
except for those rights as are herein provided.

         6. NO ASSIGNMENT. Except as otherwise provided herein, the
Non-Statutory Stock Option and the rights and privileges conferred hereby may
not be transferred, assigned, pledged, hypothecated or encumbered, and shall not
be subject to execution, attachment, garnishment or other similar legal
processes. Upon any attempt to transfer, assign, pledge, hypothecate or
otherwise encumber or dispose of the Non-Statutory Stock Option, the
Non-Statutory Stock Option and the rights and privileges conferred hereunder
shall immediately become null and void. This option may be exercised during the
lifetime of the Executive only by the Executive; provided, however, that if the
Executive is declared legally incompetent, the Executive's duly appointed legal
representative may exercise the Non-Statutory Stock Option granted hereunder in
the manner and to the extent that the Executive is entitled to exercise the
option hereunder.

         7. INCORPORATION OF THE PLAN. This Agreement incorporates the terms of
the Plan, and any modifications or amendments thereto. The Employee acknowledges
receipt of a copy of



<PAGE>   3


the Plan and agrees to be bound by all the terms and provisions thereof that are
not inconsistent with the terms of this Agreement.

         8. GOVERNING LAW. This Agreement shall be governed by the law of North
Carolina, without reference to the principles of conflicts of law thereof.


         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed as of the date first above written.


                                        PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.

                                        By:      /s/ Fredric N. Eshelman
                                            ------------------------------------
                                            Its    Chief Executive Officer
                                                --------------------------------



                                                  /s/ Grover C. Wrenn
                                            ------------------------------------
                                               Executive